PE20030335A1 - Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad - Google Patents

Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Info

Publication number
PE20030335A1
PE20030335A1 PE2002000803A PE2002000803A PE20030335A1 PE 20030335 A1 PE20030335 A1 PE 20030335A1 PE 2002000803 A PE2002000803 A PE 2002000803A PE 2002000803 A PE2002000803 A PE 2002000803A PE 20030335 A1 PE20030335 A1 PE 20030335A1
Authority
PE
Peru
Prior art keywords
obesity
systems
treatment
indan
prophylaxia
Prior art date
Application number
PE2002000803A
Other languages
English (en)
Inventor
Martin Bickel
Volker Krone
Gerhard Jaehne
Matthias Gossel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20030335A1 publication Critical patent/PE20030335A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UTILIZACION DE COMPUESTOS INDAN-1-OL-SUSTITUIDOS EN C2 DE FORMULA I DONDE R1, R2, R3, R4 SON H, F, Cl, Br, I, CN, NO2, OH, O-ALQUILO C1-C8, O-CICLOALQUILO C3-C8, O-CH2-FENILO, O-FENILO, O-CO-ALQUILO C1-C8, 5-TETRAZOLILO, ENTRE OTROS; X ES S, SO, SO2; Y ES (CH2)p; p ES 0-3; R5 ES CF3, ALQUILO C1-C18, CICLOALQUILO C3-C8, (CH2)r-COR6, CH2-CH(NHR7)COR8, FENILO, NAFTILO, BIFENILO, HETEROCICLO, r ES 1-6; R6 Y R8 SON OH, ALQUILO C1-C6, NH2; R7 ES H, CO-ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS 5-CLORO-2-METILSULFONIL-INDAN-1-ONA, 5-CLORO-2-(PROPAN-2-SULFONIL)-INDAN-1-OL, 5-CLORO-2-ETANOSULFONIL-INDAN-1-OL; 5-CLORO-2-METILSULFANIL-INDAN-1-OL. TAMBIEN SE REFIERE AL USO CON CATINAS, FENILPROPANOLAMINAS, AMFEPRAMONAS, MEFENOREX, EFEDRINAS, LEPTINA, DEXANFETAMINAS, ANFETAMINAS, FENFLURAMINAS, ENTRE OTROS. LOS COMPUESTOS TIENEN EFECTO ANOREXICO Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE OBESIDAD
PE2002000803A 2001-08-31 2002-08-21 Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad PE20030335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10142666A DE10142666A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas

Publications (1)

Publication Number Publication Date
PE20030335A1 true PE20030335A1 (es) 2003-05-20

Family

ID=7697236

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000803A PE20030335A1 (es) 2001-08-31 2002-08-21 Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Country Status (13)

Country Link
US (2) US20030134879A1 (es)
EP (1) EP1425007B1 (es)
JP (1) JP2005503397A (es)
AT (1) ATE308321T1 (es)
AU (1) AU2002336984B2 (es)
CA (1) CA2458526A1 (es)
DE (2) DE10142666A1 (es)
DK (1) DK1425007T3 (es)
ES (1) ES2250710T3 (es)
IL (2) IL160605A0 (es)
MX (1) MXPA04001852A (es)
PE (1) PE20030335A1 (es)
WO (1) WO2003020263A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
US8633252B2 (en) * 2009-01-26 2014-01-21 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
TWI799691B (zh) * 2019-03-29 2023-04-21 景凱生物科技股份有限公司 具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2345146A1 (fr) * 1976-03-23 1977-10-21 Logeais Labor Jacques Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol
DE2965279D1 (en) * 1978-07-27 1983-06-01 Schering Ag Indanyl derivatives, process for their preparation and pharmaceutical compositions containing these compounds
WO1987002035A1 (en) * 1985-10-04 1987-04-09 Maggioni-Winthrop S.P.A. Fused cycloaliphatic aminoalcohols
WO1989003681A1 (en) 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
KR19990071978A (ko) * 1995-12-06 1999-09-27 존 클라시 디렉턴 인단 다이머 화합물 및 그 약학적 용도
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CN1264384A (zh) 1997-07-16 2000-08-23 诺沃挪第克公司 稠合1,2,4-噻二嗪衍生物及其制备方法和用途
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
DE10142660A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142667B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE10142662B4 (de) * 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US7763662B2 (en) 2010-07-27
MXPA04001852A (es) 2004-06-15
IL160605A (en) 2010-12-30
EP1425007B1 (de) 2005-11-02
DE10142666A1 (de) 2003-03-20
EP1425007A1 (de) 2004-06-09
CA2458526A1 (en) 2003-03-13
WO2003020263A1 (de) 2003-03-13
AU2002336984B2 (en) 2006-10-26
ES2250710T3 (es) 2006-04-16
DK1425007T3 (da) 2006-03-13
JP2005503397A (ja) 2005-02-03
IL160605A0 (en) 2004-07-25
ATE308321T1 (de) 2005-11-15
DE50204801D1 (de) 2005-12-08
US20030134879A1 (en) 2003-07-17
US20050080057A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
NO20052739L (no) CCR5-antagonister som medikamenter
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
ATE520668T1 (de) Sigmarezeptor-inhibitoren
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
NO20081844L (no) Terapeutiske forbindelser
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
MXPA04001847A (es) Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.
PT1173176E (pt) Utilizacao de sistemas policiclicos de 2-amino-tiazole para a preparacao de medicamentos para a profilaxia ou tratamento da obesidade
BR0208038A (pt) Uso de um ou mais componentes saudáveis e método para a administração de um componente saudável.
BR0008519A (pt) Aplicação de sistemas tiazol policìclicos para apreparação de medicamentos para a profilaxia outratamento da obesidade
PE20030335A1 (es) Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
PE20030338A1 (es) Utilizacion de derivados de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
IL160603A0 (en) C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals
PE20030337A1 (es) Indan-1-onas sustituidas en c2 y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
DOP2001000253A (es) Alcanosulfonatos de fenoxifenilo.

Legal Events

Date Code Title Description
FD Application declared void or lapsed